> Details

Omar, Thoria Ahmed; El-Saeed, Gehan Kamal; Khodeer, Seham Ahmed; Dawood, Alaa Abdelsalam; El-Deeb, Sara Mahmoud; ELShemy, Asmaa Mohammed; Montaser, Belal Abdelmohsen

Vascular endothelial growth factor A with two genetic variants for prediction of mixed microvascular diabetic complications

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Vascular endothelial growth factor A with two genetic variants for prediction of mixed microvascular diabetic complications
  • Contributor: Omar, Thoria Ahmed; El-Saeed, Gehan Kamal; Khodeer, Seham Ahmed; Dawood, Alaa Abdelsalam; El-Deeb, Sara Mahmoud; ELShemy, Asmaa Mohammed; Montaser, Belal Abdelmohsen
  • Published: Springer Science and Business Media LLC, 2022
  • Published in: Egyptian Journal of Medical Human Genetics, 23 (2022) 1
  • Language: English
  • DOI: 10.1186/s43042-022-00303-y
  • ISSN: 2090-2441
  • Keywords: Genetics (clinical)
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Vascular endothelial growth factor (VEGF) is a signal protein, induces cell proliferation, and enhances the permeability of the endothelial cells. <jats:italic>VEGF-A</jats:italic> gene is highly polymorphic, with different near-gene variants at varied frequencies linked with altered VEGF protein expression, type 2 diabetes mellitus (T2DM) susceptibility, and associated microvascular complications. The present study aimed to investigate the role of two genetic variants of <jats:italic>VEGF-A</jats:italic>, − 583C &gt; T (rs3025020) and + 936 C/T (rs3025039), for predicting mixed microvascular complications in T2DM. This case–control study was performed on 26 T2DM patients with mixed microvascular complications and 26 apparently healthy individuals, as a control group. Clinical, neurological, funds examinations, and biochemical laboratory investigations were conducted on all groups. The serum level of VEGF-A was measured using ELISA. Genotyping of <jats:italic>VEGF-A</jats:italic> was performed by real-time PCR allelic discrimination system.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>Serum level of VEGF-A was significantly increased in T2DM with mixed complications. T allele of <jats:italic>VEGF-A</jats:italic> rs3025020 showed higher frequency among T2DM patients with mixed complications than in control group [OR 2.67; 95% CI 1.03–6.91; <jats:italic>p</jats:italic> = 0.04], while CT genotype and T allele of <jats:italic>VEGF-A</jats:italic> rs3025039 had a high frequency in mixed complication group [OR 4.08; 95% CI 1.32–17.44; <jats:italic>p</jats:italic> = 0.01 and OR 4.02; 95% CI 1.52–10.63; <jats:italic>p</jats:italic> = 0.004, respectively].</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>VEGF-A increased the level contributed in the pathogenesis of mixed diabetic microvascular complications. T allele of <jats:italic>VEGF-A</jats:italic> rs3025020, CT genotype, and T allele of <jats:italic>VEGF-A</jats:italic> rs3025039 had the highest frequency in mixed diabetic microvascular complications, so they were considered risk genes for mixed diabetic microvascular complications.</jats:p> </jats:sec>